Moderna Inc
Change company Symbol lookup
Select an option...
MRNA Moderna Inc
CHE Chemed Corp
ASTA WorldFlix Inc
$NQDM15LMCADN Nasdaq Developed Markets Telecommuni
BFZ BlackRock California Municipal Income Trust
CAR Avis Budget Group Inc
GIS General Mills Inc
VLN Valens Semiconductor Ltd
CIF MFS? Intermediate High Income Fund
LVOXW LiveVox Holdings Inc *W EXP 06/18/2026
Go

Health Care : Biotechnology | Large Cap Blend
Company profile

Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger RNA (mRNA). The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. The Company develops technologies that enable the development of mRNA medicines for diverse applications. The Company has created modalities, including Prophylactic vaccines, Systemic secreted and cell surface therapeutics, Cancer vaccines, Intratumoral immuno-oncology, Localized regenerative therapeutics, and Systemic intracellular therapeutics. Its diverse development pipeline which consists of 27 development candidates across its 24 programs.

Closing Price
$324.21
Day's Change
-7.67 (-2.31%)
Bid
--
Ask
--
B/A Size
--
Day's High
341.55
Day's Low
318.50
Volume
(Average)
Volume:
17,239,834

10-day average volume:
15,797,139
17,239,834

Company Profile

Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger RNA (mRNA). The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. The Company develops technologies that enable the development of mRNA medicines for diverse applications. The Company has created modalities, including Prophylactic vaccines, Systemic secreted and cell surface therapeutics, Cancer vaccines, Intratumoral immuno-oncology, Localized regenerative therapeutics, and Systemic intracellular therapeutics. Its diverse development pipeline which consists of 27 development candidates across its 24 programs.

Valuation Ratios

Price/Earnings (TTM)
40.13x
Price/Sales (TTM)
18.49x
Price/Book (MRQ)
19.33x
Price/Cash Flow (TTM)
36.10x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

September 2021
Current Month
14.3M
Previous Month
14.3M
Percent of Float
3.93%
Days to Cover
1.0913 Days

Share Information

MRNA is in a share class of common stock
Float
364.7M
Shares Outstanding
403.6M
Institutions Holding Shares
1,258
56.80%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

  • Noubar B. Afeyan
  • Stephen HogePres.
  • Stephane BancelCEO
  • David MelineCFO
  • Tracey Franklin

Address

Insider Trading

During the most recent quarter, 1M shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.